Welcome, Guest. Please login or register.
May 06, 2021, 01:50:38 am

Login with username, password and session length


Members
Stats
  • Total Posts: 759540
  • Total Topics: 64404
  • Online Today: 249
  • Online Ever: 4912
  • (November 13, 2019, 02:56:14 am)
Users Online
Users: 0
Guests: 238
Total: 238

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Islatravir-Based HIV Regimen Fails Few Study Participants  (Read 476 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 17,040
  • Twitter @JimAllenDublin
    • HIV Lessons
Islatravir-Based HIV Regimen Fails Few Study Participants
« on: October 13, 2020, 05:15:30 am »
To be honest, it doesn't seem like terrible results at 48 & 96 weeks if you ask me. The PLHIV were treatment native and I think it's fair to say they tend to have VL blips with any treatment more frequent at first. Although, it's a small sample size.

In full POZ.com writeup:
https://www.poz.com/article/islatravirbased-hiv-regimen-fails-study-participants

in Short:

Quote
The study enrolled 121 people with HIV, randomized initially to received islatravir at either 0.25 milligrams, 0.75 mg or 2.25 mg daily plus Pifeltro (doravirine) and lamivudine daily; or they received a fixed-dose combination of Delstrigo (doravirine/tenofovir disoproxil fumarate/lamivudine). The study was set to run for 96 weeks.

Those in the islatravir groups who had a fully suppressed viral load (less than 50) 20 weeks into the study or later were taken off lamivudine at their next clinic visit.

Orkin and her colleagues defined virologic failure as having a viral load of 50 or greater after having achieved full viral suppression at any time during the study, called a rebound. Or this outcome was defined as not achieving a viral load below 50 by week 48 of the study, called a nonresponse.

At week 96 of the study, 86.2% (25 of 29) of those who received 0.25 mg of islatravir had a fully suppressed viral load, as did a respective 90.0% (27 of 30) and 67.7% (21 of 31) of those who received 0.75 mg and 2.25 mg the drug. By comparison, 80.6% (25 of 31) of those who received Delstrigo had a viral load below 50.

During the first 48 weeks of the trial, six participants discontinued treatment due to virologic failure. This included two rebounders each in the 0.25 mg and 0.75 mg of islatravir groups, one nonresponder in the 2.25 mg group and one rebounder in the Delstrigo group.

Following the 48-week mark, one additional participant discontinued treatment due to virologic failure. This person, who was in the 2.25 mg group, saw their virus rebound to 70 at the 72-week point.

All those who experienced virologic failure had a viral load between 50 and 79. This meant that none had a viral load high enough to conduct resistance testing on their virus.

After the seven people who discontinued treatment switched to new HIV regimens, three—one each from the 0.25 mg and 0.75 mg groups and one from the Delstrigo group—continued to have a viral load that was above 50 and yet remained low.

« Last Edit: October 13, 2020, 05:18:00 am by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.